Cost-Effective Innovation

November 12, 2015
Tim Mayleben
President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices.  The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious.  But these drugs are priced at… Read More

What’s Your “Why”?

May 13, 2015
Tim Mayleben
President and Chief Executive Officer

This past weekend Esperion participated, for the 15th year, in the American Heart Association’s (AHA) annual Heart Walk to raise money for cardiovascular disease research. It is hard for me to put into words the inspiring nature of these events – as patients, survivors, doctors and others join together to combat what continues to be… Read More

Posted In: Tim Mayleben

The Promise of ETC-1002 for Patients at Risk of Cardiovascular Disease

October 15, 2013
Noah Rosenberg
Chief Medical Officer

Many years ago, as an attending physician in an academic emergency department, I was surprised to see a number of patients presenting with advanced cardiovascular disease (CVD). What made this so unusual was that these patients had no known “traditional” CVD risk factors, such as smoking or high blood pressure, but were all relatively young–in… Read More

Posted In: Company News

Going with Your Gut

August 30, 2013
Roger Newton, Ph.D., F.A.H.A.
Executive Chairman and Chief Scientific Officer

Sometimes in science, you have to go with your gut. Years ago, my gut instinct told me that a drug I was working on would be successful, even though it was still early in development and several effective competitors were already on the market. I believed in this drug so much that I begged the… Read More